Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

PaxMedica, Inc. Common Stock (PXMD)

2.43   -0.27 (-10%) 01-27 16:00
Open: 2.73 Pre. Close: 2.7
High: 2.73 Low: 2.34
Volume: 362,523 Market Cap: 29(M)

Technical analysis

as of: 2023-01-27 4:47:20 PM
Stoxline posted a STRONG SELL today, same as yesterday. Downward movement continues.
Target: Six months: 3.3     One year: 4.36
Support: Support1: 1.36    Support2: 1.13
Resistance: Resistance1: 2.83    Resistance2: 3.74
Pivot: 2.68
Moving Average: MA(5): 2.9     MA(20): 2.53
MA(100): 2.38     MA(250): 0
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 42.7     %D(3): 60.9
RSI: RSI(14): 48.9
52-week: High: 6.57  Low: 1.36
Average Vol(K): 3-Month: 1,018 (K)  10-Days: 736 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PXMD ] has closed above bottom band by 29.9%. Bollinger Bands are 0% narrower than normal.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.73 - 2.76 2.76 - 2.77
Low: 2.3 - 2.32 2.32 - 2.34
Close: 2.4 - 2.44 2.44 - 2.46

Company Description

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.

Headline News

Fri, 27 Jan 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace

Wed, 25 Jan 2023
Short Squeeze Stocks: 5 Stocks Wall Street Really DOESN'T Want to ... - InvestorPlace

Sun, 22 Jan 2023
Wall Street Breakfast: The Week Ahead - Seeking Alpha

Fri, 20 Jan 2023
2023-01-20 | NDAQ:PXMD | Press Release | PaxMedica Inc. - Stockhouse

Wed, 18 Jan 2023
Pre-market Movers: FUV, CYAD, ATXI, CSSE, PXMD… - RTTNews

Wed, 18 Jan 2023
Pre-market Movers: FUV, CYAD, ATXI, CSSE, PXMD… - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 1 (M)
% Held by Insiders 93.6 (%)
% Held by Institutions 0 (%)
Shares Short 140 (K)
Shares Short P.Month 397 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -4 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.